Propel Your Career at THT

Submit your abstracts of original research for the opportunity to present to thousands of your colleagues worldwide. Research can be in the form of clinical studies, basic science investigations, or preclinical studies and must be relevant to heart failure. Your abstracts must convey original research but can include portions of previous abstracts and/or manuscripts presented elsewhere.

Accepted abstracts will be reviewed by the editors of JACC:HF, Circ:HF, Heart Failure Reviews, Structural Heart, JSCAI which may result in invitations for submission of brief reports and full papers.

If you have single-patient case report, please submit it as a challenging case, regardless of its novelty.

Guidelines

Character limit is 2,200, including spaces.
Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

Notification

Submitters will be notified by mid-January.

SUBMIT NOW

Fellows (cardiology, heart failure, surgery, intensive care, etc.), medical residents and other professionals in other stages of training are welcome to submit challenging heart failure management cases. The THT directors will carefully review each submitted case, and the best will be selected for presentation. Additionally, the top five cases will be featured on TCTMD^®.

Guidelines

Character limit is 2,450 total for case summary, history, diagnostic tests, procedure, conclusion, comments. PowerPoint slide presentation highlighting your case is optional. Images: 10 MB. Video formats accepted: 30 MB mpeg, wmv, avi, mov, mpg, mp4.
Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

Notification

Submitters will be notified by mid-January.

SUBMIT NOW

Submit clinical studies, basic science investigations, or preclinical studies relevant to some aspect of heart failure, including diagnosis, therapy, or monitoring. Case reports or case series may be submitted for consideration under Fellows Challenging Cases.

Eligibility

All current fellows, interns, residents, and medical students in training can submit an abstract. The author submitting the abstract should have contributed substantially to the study, and this will be a major part of the grading.

Selection and Presentation

• The five highest-rated submissions will be named as finalists.
• Finalists will deliver an oral presentation during a dedicated fellows’ research session.
• The five finalist presentations will be evaluated by an expert panel that will select the winning abstract.
• Finalist fellows will be interviewed and featured on TCTMD^®.
• All accepted abstracts will be presented as posters that will appear in the lobby near the main lecture hall for the entire duration of the meeting.

Guidelines

Total character limit is 2,200, including spaces.
Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

Notification

Submitters will be notified by mid-January.

SUBMIT NOW

Submit your novel ideas for clinical study designs or registry studies to meaningfully advance the care of patients presenting with cardiogenic shock (either due to acute myocardial infarction, decompensated chronic heart failure, or other causes).

Guidelines

Total character limit is 2,200 characters (including spaces).

• Study Hypothesis
• Enrollment Criteria
• Primary and Key Secondary Endpoints
• Estimated Sample Size

Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

Submitters will be notified by mid-January.

SUBMIT NOW

Submit your late-breaking clinical science and first-in-human early feasibility studies. These are typically:

• Primary or important secondary endpoint results of prospective, randomized clinical trials.
• First-time presentations of first-in-human experiences with novel devices or drugs.
• Results of pilot studies of drugs or novel devices.
• Large-scale, impactful single/multicenter registries.

Please note that the following rarely qualify as late-breaking clinical science submissions and, instead, should be submitted as abstracts: preclinical studies, early first-in-human device studies, and meta-analyses.

Accepted abstracts will be reviewed by the editors of JACC:HF, Circ:HF, Structural Heart, JSCAI which may result in invitations for submission of brief reports and full papers.

Embargo

Accepted late-breaking science and first-in-human early feasibility studies are strictly embargoed until time of presentation.

Guidelines

Total character limit is 3,250, including spaces (primary endpoints: 550-character limit; secondary endpoints: 550-character limit; funding sources: 500-character limit). Upload .png or .jpg files only.

Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

SUBMIT NOW

Enter the THT Shark Tank! Submit your concept-stage novel technologies in heart failure for a chance to present to a panel of expert judges. 

Your submission must be relevant to technology for the monitoring, diagnosis, or treatment of heart failure and address all the following:

• Unmet clinical need/field of use.
• Technology differentiation and competitive landscape.
• IP position/landscape.
• Summary of preclinical and/or first-in-human data.
• Regulatory pathway/strategy and commercialization strategy.

Opportunity to Submit to JACC: Basic to Translational Science (BTS)

Building on the success of last year’s THT Shark Tank issue of the publication, THT will be collaborating with the JACC: Basic to Translational Science (BTS) for the second annual dedicated issue. If your submission is accepted for presentation at THT 2025, you will be invited to additionally submit a brief research letter for publication in the journal.

Guidelines

Describe clinical indication for innovative device or technology. The total character limit is 2,450, including spaces. Submit 15–20 PowerPoint slides covering aspects of the technology.
Images will reduce your character limit by 600.
Tables will reduce your character limit by 300.

Submitters will be notified by mid-January.

SUBMIT NOW